341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
The Readout Loud
The Biotech Innovation Dilemma
This chapter explores the evolving landscape of drug development through the lens of biotech companies Absci and Generate, focusing on their antibody candidates for COVID and asthma. It examines the skepticism surrounding the innovation and efficacy of AI-assisted drug design, as well as the broader implications of transparency in the biotech industry.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
